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Introduction
Atrial fibrillation (AF) is the most common arrhythmia observed in clinical practice, with prevalence increasing with age. It has been estimated that over 6 million people in the European Union have AF and the number has doubled during the last 50 years due to aging of the population [1] . AF increases mortality and the risk of stroke and decreases quality of life [2] .
Two strategies of AF treatment can be applied: rhythm control or rate control [1] . A key procedure in the rhythm control strategy is cardioversion to sinus rhythm (SR), which can be achieved through pharmacologic or electrical means. Electrical cardioversion (ECV) is proven more effective than pharmacological cardioversion (PCV) [3] , but it is costly, requires presence of an anesthesiologist and can be time-consuming.
The aim of the present manuscript is to provide a review of treatment patterns for the cardioversion of patients with recent-onset AF in hospital setting in Poland and document the success rate of various cardioversion procedures.
Methods

Study design
RHYTHM-AF was a prospective observational study conducted in 10 countries: Australia, Brazil, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden, and the United Kingdom. Patients with recent-onset of AF considered for cardioversion were enrolled from participating hospitals and acute care centers between May 2010 and June 2011 [4] . In this manuscript, only results from Poland will be presented.
Study population
Centers recruiting patients were selected as representatives of this way of treating AF in the participating countries. All patients considered for the study were at least 18 years old with documented AF, confirmed by electrocardiogram and cardioversion was one of the planned therapeutic options. All patients signed an informed consent. Only patients who were already enrolled in the current trial, otherwise enrolled in a separate trial, and patients with atrial flutter were excluded.
PCV was considered successful if SR or atrial rhythm was obtained within 24 h following the initiation. Time to SR was, however, noted separately. ECV was defined as successful if SR was obtained and maintained for at least 10 min following the last shock.
All patient data were collected via a remote web based data collection form using the multilingual software solution EBogen © , developed by the IHF Ludwigshafen, Germany (the coordinating center for the study).
Statistical analyses
All data are presented as mean ± standard deviation, median and interquartile (IQR) range or number and percent of population, depending on characteristic of the parameter. All comparisons were made using c 2 or Kruskal-Wallis tests.
Results
In Poland, 501 patients in 15 centers were included into the analyses. Major characteristics of the study group are shown in Table 1 . Two hundred and ninety four patients underwent cardioversion (148 -primary ECV, 146 -primary PCV), while in 207 patients no cardioversion was attempted. In almost half of these patients (n = 92, 44.4%), cardioversion was planned following the discharge, in 26.6% (55 patients) there was spontaneous conversion to SR. Flow of the patients and detailed reasons for not attempting to cardioversion are shown in Figure 1 .
Comparison between primary ECV and primary PCV patients
Clinical characteristic of patients who primarily underwent ECV included younger aged and less frequently women than those cardioverted pharmacologically. The distribution of concomitant diseases (hypertension, diabetes, coronary artery disease) was comparable between the ECV and PCV groups (and so was CHADS 2 and CHA 2 DS 2 --VASc score) with the exception of heart failure and valvular heart disease -these patients more frequently underwent ECV. Major differences between ECV and PCV patients were AF characteristics: among patients who underwent ECV, paroxysmal AF was less frequent, persistent AF was more common, and the duration of the longest previous episode was different (91.3 vs. 0.8 days), as was the duration of the current episode (57.0 vs. 0.0 days).
Electrical cardioversion
One hundred and forty eight patients underwent primary ECV (50.3% of patients who underwent any cardioversion). The total number of patients who underwent external ECV (including those converted from PCV) was 165 (98.2%). Mean energy of the first shock was 157.7 ± 47.2, with no differences between successful and unsuccessful cardioversion. One ECV was done transesophageally (but was unsuccessful), and two were made from implantable cardioverter-defibrillator (both successful). An anesthesiologist was present in 135 (81.8%) cases of all ECVs. SR was eventually obtained in 148 patients among those receiving ECV.
Comparing patients with successful and unsuccessful primary ECV, the only parameter lower in patients with successful primary ECV was the number of previous symptomatic episodes ( Table 2 ). All patients except for one were discharged from hospital. One hundred and fourteen (86.4%) patients with a successful first ECV and 3 (17.6%, p < 0.0001) with an unsuccessful ECV were in SR at discharge.
Pharmacological cardioversion
One hundred and forty six (49.7%) patients primarily underwent PCV. The primary reason for admission was AF in 121 (82.9%) patients. Other reasons for admission included acute coronary Abbreviations -see Table 1 www.cardiologyjournal.org syndrome in 6 (4.1%) patients, stable coronary disease in 5 (3.4%) patients, heart failure in 4 (2.7%) patients, and valvular heart disease in 3 (2.1%) patients. The median time to initiation of cardioversion among those undergoing primary PCV was 2:14 h (IQR 0:30-17:50). Among these patients, the median time to reach SR was 180 min (IQR 72-740). A median of total length of hospital stay among patients with primary PCV was 70:38 h (IQR 17:50-99:03). Clinical characteristics among the amiodarone, propafenone, beta-blockers (BB) and "other" groups were not statistically different (Table 3) . AF as the primary reason for admission was the least frequent among patients in the amiodarone group; other AF characteristics were not significantly different between the groups (Table 4 ). The dosage of the drugs and the route of administration are shown in Table 5 . The most popular BB was metoprolol (88.2% of the patients treated only with BB and 87.8% of all the patients treated with BB). Nine (11.5%) patients treated initially with amiodarone were also treated with propafenone (all intravenously, a median dose of 140 mg). Primary PCV was successful in 110 (75.3%) patients. In 17 (10.9%) patients, ECV was performed following unsuccessful PCV and all were successful (number of shocks 1.1 ± 0.3, first shock 129.1 ± 55.6 J). In 2 (1.4%) patients, conversion from AF into atrial flutter or atrial tachycardia was observed. Differences in successful conversion between groups were not statistically significant: from 69.4% in the propafenone group, to 80.0% in the other drug group (p = 0.90). The time to reach SR was the longest in the amiodarone group and the shortest in the BB group (p < 0.01), with the same trend in duration of hospital stay (p < 0.0001) ( Table 6) .
None of the echocardiographic or clinical parameters was different in patients with successful primary PCV in comparison with unsuccessful primary PCV. The only significant difference was in the number of the first detected episode ( Table 2 ). All patients except for two were discharged from hospital. One hundred and six patients (96.3%) with the initial PCV successful and 19 (52.8%) patients (p < 0.0001) with the first PCV unsuccessful were in sinus/atrial paced rhythm upon discharge.
Complications and adverse events
During the hospital stay, 14 (2.8%) complications and adverse events were recorded. Among them, there was 1 transient ischemic attack, 1 pulmonary embolism, 2 exacerbations of heart failure, 1 ventricular fibrillation, 1 syncope and 5 episodes of sinus syndrome insufficiency.
No stroke, major bleeding, torsade de pointes or hypotension were observed during the hospitalization.
Discussion
In the present manuscript, we document characteristics and current treatment patterns of patients who were admitted to the hospital to un- Table 6 . Results of primary pharmacological cardioversion (PCV). *This include amiodarone + beta-blockers and propafenone + beta-blockers; **As the only therapy; IQR -interquartile range www.cardiologyjournal.org dergo cardioversion of AF. General characteristics of the whole group and comparison with other registries are described in another publication [5] . We show safety and effectiveness of cardioversion in a "real life" registry, with consecutive patients included, with wide inclusion criteria and very limited exclusions.
The RHYTHM-AF registry shows statistics of the hospitalized patients with AF who underwent rhythm control strategy. Out of all 501 patients in the Polish RHYTHM-AF registry, 207 (41.3%) did not undergo cardioversion, but this did not change rhythm control strategies. The most common reasons were planned cardioversion in the future and spontaneous SR restoration (68.2% for both reasons). Contraindications to cardioversion were found only in ~10% of all population; these included uncertain duration of current episodes of AF, left atrial thrombus or spontaneous echo contrast. Left atrial thrombus was found in 16 (3.2%) patients (in a large German cohort of over 3,000 patients with AF who underwent TEE, the frequency of thrombus in the left atrium was comparable [6] ). In 8 patients, the rhythm control strategy was changed into rate control (cardioversion was not attempted because of size of the left atrium).
The mode of cardioversion (primary PCV and primary ECV) was largely dependent on the type of AF. Among patients who underwent ECV, paroxysmal AF was less frequent and persistent AF was more common, duration of the longest previous episode and current episode were completely different. This is consistent with current guidelines and previous studies [1, 3] .
Effectiveness of ECV in our registry was comparable to that reported in the literature (78-97%) [7] [8] [9] [10] . Although some data suggest that in AF, 200 J energy should be started, especially in non--paroxysmal AF [11] , we show that about 160 J energy may also be effective.
Pharmacological cardioversion was performed almost exclusively in patients with paroxysmal or first detected episodes of AF. According to current guidelines [1] , almost all amiodarone patients were treated intravenously, oral formulation of propafenone was more common (71.8%). In patients treated with propafenone and amiodarone, the addition of BB was considered a supplementary therapy, so patients treated with propafenone and propafenone with BB (or amiodarone and amiodarone in combination with BB) were analyzed together. Separate analyses were performed for patients treated with BB alone. Demographic characteristics of patients treated with amiodarone, propafenone and BB were not statistically different, although hyperlipidemia and coronary disease occurred less frequently among patients treated with BB, and none of these patients had a history of heart failure or myocardial infarction. Alternatively, although propafenone is contraindicated in patients with structural heart disease, 30% of patients treated with propafenone had a history of coronary disease, 25% a history of myocardial infarction and 25%, a history of heart failure. The other problem is propafenone dosing -although separate dosing for intravenous and oral applications is not available, we can conclude that oral doses given to the patients are lower than recommended in the guidelines [1] . Amiodarone dosing seems to be adequate. Of special interest is the successful conversion rate in the small (n = 17) group of patients treated with BB as the only therapy -76.5%. Previous (although very old) experiences with metoprolol were not encouraging with only 13% rate of conversion [12] . Time to reach SR in patients treated with BB was also very short (median was 68 min), especially that almost half of the patients were treated orally. One might speculate that at least some of these episodes of AF would terminate spontaneously. Still, in relatively healthy populations with numerous previous episodes of AF that terminated spontaneously, adding a BB may be helpful in restoring SR.
The time to reach SR was the longest in patients treated with amiodarone and the shortest in patients treated with propafenone. This is consistent with other observations -in a meta-analysis, efficacy of cardioversion of AF with amiodarone was inferior to class Ic drugs for up to 8 h but no difference was observed at 24 h [13] . There were statistically significant differences in hospitalization time between patients treated with various pharmacological agents in PCV (with the longest duration being among patients in the amiodarone group), which may, in part, be due to the highest percentage of patients for whom AF was not a primary reason for admission into the amiodarone group, as well as the fact that amiodarone is known to have a far longer half-life, and takes a longer time to be effective [13] .
We did not observe any clinical or echocardiographic parameters to vary significantly by the success of either primary PCV or ECV. Rate of complications was rather low, with single patients suffering serious complications including myocardial infarction, pulmonary embolism, or heart failure. A recent meta-analysis of AF cardioversion in emergency department shows comparable results [14] .
Limitations of the study
This is one of a few studies showing fate of patients with AF who are hospitalized with an intention to be cardioverted. Thanks to wide inclusion criteria, patients from the cohort are likely to reflect real life patients. This was a purely observational study, and so by design, has certain limitations on the types of conclusions which can be drawn. Treatment groups were not randomized, but rather reflect real-world treatments, where they are given at the physicians' discretion, as were diagnostic tests and concomitant treatments, which were not made in a uniform fashion (for example echocardiography).
Conclusions
Less than 60% of the patients with AF admitted to the hospital with the intention to terminate arrhythmia eventually underwent an attempt of conversion to SR. Primary ECV was chosen in 51% of patients and was successful in ~90% of the patients. PVC was successful in ~75% of the patients. Amiodarone and propafenone were most commonly used with comparable efficacy. Rates of complications were low, with ~2.8% of patients experiencing adverse events during hospitalization.
